Aveanna Healthcare (NASDAQ:AVAH) CEO Jeff Shaner Sells 90,000 Shares

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) CEO Jeff Shaner sold 90,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $11.50, for a total transaction of $1,035,000.00. Following the sale, the chief executive officer directly owned 2,561,972 shares in the company, valued at $29,462,678. This represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Aveanna Healthcare Trading Up 4.1%

Shares of NASDAQ AVAH opened at $13.70 on Tuesday. The company has a 50-day moving average of $9.71 and a two-hundred day moving average of $7.95. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 4.47. The company has a market cap of $2.99 billion, a PE ratio of 11.14, a P/E/G ratio of 0.92 and a beta of 1.90. Aveanna Healthcare Holdings Inc. has a 1-year low of $5.93 and a 1-year high of $13.98.

Aveanna Healthcare (NASDAQ:AVAH) last released its earnings results on Thursday, August 13th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.05. Aveanna Healthcare had a net margin of 10.56% and a return on equity of 80.70%. The company had revenue of $670.48 million for the quarter, compared to the consensus estimate of $638.61 million. As a group, equities analysts expect that Aveanna Healthcare Holdings Inc. will post 0.68 earnings per share for the current fiscal year.

Key Headlines Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Royal Bank of Canada raised its price target from $10 to $16 and upgraded its rating to “outperform,” implying additional upside from the stock’s recent trading level. Benzinga analyst coverage
• Positive Sentiment: Truist Financial lifted its price target from $11 to $15 while maintaining a “hold” rating. The higher target reflects improved valuation expectations, even though Truist remains cautious on the shares. Benzinga analyst coverage
• Negative Sentiment: Insiders and major shareholders disclosed approximately 48.6 million shares of sales at an average price of $11.50, worth roughly $558.5 million. Sellers included Paul R. Vigano, Robert M. Williams Jr., and J.H. Whitney Equity Partners V, as well as CEO Jeff Shaner, director Rodney D. Windley, and insider Edwin C. Reisz. Although the sellers retained sizable positions, the volume of stock coming to market may pressure AVAH and raise questions about shareholder confidence. SEC insider transaction filing

Institutional Investors Weigh In On Aveanna Healthcare

Hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd lifted its stake in shares of Aveanna Healthcare by 252.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock valued at $27,000 after acquiring an additional 2,400 shares during the last quarter. Quantbot Technologies LP bought a new stake in Aveanna Healthcare in the 2nd quarter worth about $43,000. Summit Securities Group LLC bought a new stake in shares of Aveanna Healthcare in the first quarter worth $53,000. Oxford Asset Management LLP purchased a new position in shares of Aveanna Healthcare in the second quarter worth approximately $64,000. Finally, C M Bidwell & Associates Ltd. purchased a new stake in Aveanna Healthcare in the second quarter worth about $69,000. Institutional investors own 87.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on AVAH shares. Barclays lifted their price target on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Raymond James Financial lifted their price target on shares of Aveanna Healthcare from $13.00 to $15.00 and gave the company a “strong-buy” rating in a research report on Friday, August 14th. BMO Capital Markets raised their target price on shares of Aveanna Healthcare from $10.00 to $14.00 and gave the company an “outperform” rating in a research report on Friday, August 14th. Stephens raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $10.00 to $11.00 in a research note on Friday, May 15th. Finally, Royal Bank Of Canada increased their target price on Aveanna Healthcare from $10.00 to $16.00 and gave the stock an “outperform” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.89.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.